Business Context and Reporting Period
This Form 8-K Current Report was filed by TuHURA Biosciences, Inc. on June 17, 2026. The filing addresses Item 5.08 regarding Shareholder Director Nominations and the scheduling of the Company's 2026 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing regarding corporate governance and does not contain financial performance data.
Material Changes
The primary material change disclosed is the rescheduling of the 2026 Annual Meeting of Stockholders. The meeting is now set to be held virtually on August 18, 2026. This date represents a change of more than 30 days from the anniversary of the 2025 Special Meeting held on June 23, 2025.
Guidance, Outlook, and Management Commentary
Management has announced that the 2026 Annual Meeting will be held virtually. Due to the change in the meeting date exceeding 30 days from the prior anniversary, the standard deadlines for stockholder proposals under Rule 14a-8 and director nominations under the Company's proxy access rights no longer apply. Instead, new deadlines have been established:
- Rule 14a-8 Proposals: Must be received by June 27, 2026.
- Proxy Access Director Nominations: Must be received by the close of business on June 27, 2026.
- Bylaw Proposals and Director Nominations: Must be received by the close of business on June 27, 2026.
- Universal Proxy Rule (Rule 14a-19): Notice for soliciting proxies for director nominees other than the Company's nominees must be provided by June 27, 2026.
The filing explicitly states that any adjournment or postponement of the 2026 Annual Meeting will not commence a new time period for submitting these proposals or notices.
Important Facts for Investors to Verify
- Verify the virtual meeting date of August 18, 2026, and ensure access to the Definitive Proxy Statement on Schedule 14A for further details.
- Confirm the strict deadline of June 27, 2026, for submitting any stockholder proposals or director nominations to be considered for the 2026 Annual Meeting.
- Note that the filing does not contain financial results; investors should refer to the most recent 10-K or 10-Q for financial data.